modelS01AE07
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Moxifloxacin | |
| ATC code: | S01AE07 | route: | ocular |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 0.02 | L |
| clearance: | 0.003 | L/h |
| other parameters in model implementation | ||
Moxifloxacin is a fourth-generation fluoroquinolone antibiotic used for the treatment of bacterial infections. It is active against a broad spectrum of Gram-positive and Gram-negative pathogens and is commonly used to treat respiratory tract infections, skin infections, and certain types of conjunctivitis. Moxifloxacin with ATC code S01AE07 refers specifically to its ophthalmological (eye drop) use. The drug is approved for use in many countries and is generally well tolerated.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult volunteers after single and repeated topical ocular administration.
References
Segreti, J, et al., & Bertino, JS (2012). Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 28(1) 3–11. DOI:10.1089/jop.2011.0072 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21999341
Chang, MH, & Fung, HB (2010). Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis. Clinical therapeutics 32(3) 454–471. DOI:10.1016/j.clinthera.2010.03.013 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20399984
Torkildsen, G, & O'Brien, TP (2008). Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. Clinical therapeutics 30(11) 2005–2014. DOI:10.1016/j.clinthera.2008.10.020 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19108788
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)